Substantial doubt about the company's ability to continue as a going concern.
“management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Dec 3, 2025; less than a full year is stored.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMII
this stock
Drugs Made In America Acquisition II Corp.
|
$650.38M | +3.3% | — | — | 0.0% |
|
VYLR
Vylor Inc.
|
$48.01B | — | — | — | 2.2% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$606.10M | +3.4% | — | — | 0.0% |
|
BCSS
Bain Capital GSS Investment Corp.
|
$596.85M | +1.4% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMII | +0.3% | +0.3% | +2.2% | +0.3% | +3.3% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | +1.0% | +1.7% | -0.3% | -1.2% | -9.2% |
